Ribavirin was initially designed as a direct antiviral agent for the treatment of distinct viral disease, and later on proved to be a pivotal combination partner to enhance efficacy of IFN-based therapy and probably also of direct antiviral agents in chronic hepatitis C [2], [26]. Here, IFNA1 is linked to viral load.